摘要
目的 探讨逆转录聚合酶链式反应(RT-PCR )方法检测乳腺癌患者外周血表皮生长因子受体(EGFR)mRNA作为乳腺癌循环肿瘤细胞标志的可能性及意义。方法 以转录聚合酶链式反应(RT-PCR)方法,分别对40例乳腺癌患者和30例健康人静脉血进行EGFRmRNA检测,同时与目前研究较多的循环上皮细胞标志:细胞角质蛋白CK-19的mRNA做比较。结果 在30例健康人外周静脉血中没有发现EGFRmR NA的表达( 0% ),但有8例CK-19阳性( 26. 7% )。而40例乳腺癌患者检测出13例EGFRmRNA阳性(32. 5% ),与正常人相比P<0. 01,两组间存在显著性差异;CK-19的mRNA阳性例数为14 (35. 0% ),与正常人相比P>0. 05,两组间无统计学差异。通过免疫组化检测到25例( 62. 5% )的肿瘤组织中EGFR阳性,所有外周血中EGFRmRNA阳性的病例,相应的原发肿瘤病灶中EGFR蛋白均为阳性,组织中EGFR蛋白高表达的患者外周血EGFRmRNA检出率也高(P<0. 01)。26例初治患者中5例EGFRmRNA阳性(19. 2% ),14例复治患者中8例EGFRmRNA阳性(57. 1% ),两组相比P<0. 05,存在显著性差异。6例曾使用过紫杉醇类药物挽救化疗的转移性患者中1例EGFRmRNA阳性(16. 7% ), 8例未使用过紫杉醇类药物挽救化疗的转移性患者中7例EGFRmRNA阳性(87. 5% ),两组相比P<0. 05,存在显著性差异。
Objective To evaluate the feasibility of de tecting epidermal growth factor receptor (EGFR) mRNA by reverse transcription po lymerase chain reaction(RT-PCR)in peripheral blood of patients with breast cance r and to explore its significance. Methods RT-PCR assay w as applied to detect the expression of EGFR mRNA in the peripheral blood of 40 p atients with breast cancer and in 30 healthy donors. The result of EGFR mRNA was compared with that of known marker of circulating epithelial cells:CK-19. Results In peripheral blood from 30 healthy donors,none of EGF R mRNA was detected,but the positivity of CK19 mRNA expression was 26.7% (8/ 30) .In contrast ,EGFR mRNA was detected in 13 of 40(32.5%)patients with breast canc er,compared with healthy donors (P<0.01),there was significant d ifference between the two groups. CK-19 mRNA was found in 14 of 40(35.0%), compa red with healthy donors (P>0.05) and there was no statistical di fference. On the other hand, the expression of EGFR was observed in 25(62.5%) of tumor tissues by immunohistochemistry. We found that all patients who expressed EGFR mRNA in peripheral blood were also expressing EGFR in primary tumors. Pati ents with a high expression of EGFR in tumoral breast tissues display high expre ssion of EGFR in peripheral blood as well(P<0.01). EGFR mRNA w as expressed in 5 of 26(19.2%) breast cancer patients without any treatments bef ore, but the positivity for EGFR mRNA expression was 57.1% (8/ 14) in breast can cer patients who have received treatments before. There is significant differenc e between two groups above (P<0.05). Expression of EGFR mRNA was detected in 1of 6 (16.7%) metastatic breast cancer patients who have received P aclitaxel involved salvage chemotherapy, however, the positivity for EGFR mRNA e xpression was 87.5% (7/ 8) in them who have never received Paclitaxel contained salvage chemotherapy, there was significant difference between two groups ( P<0.05). Conclusion CK-19 mR NA showed no dia gnostic value as marker of circulating tumor cells in breast cancers. However, E GFR mRNA in blood may be a useful marker of circulating tumor cells in breast ca ncers. Detecting EGFR mRNA in peripheral blood of patients with breast cancer us ing RT-PCR can be used as a prognostic indicator. Paclitaxel may reduce the risk of relapse and metastasis of breast cancer.
出处
《现代肿瘤医学》
CAS
2005年第2期154-158,共5页
Journal of Modern Oncology
基金
高等学校优秀青年教师教学科研奖(TRAPOYT99216)
高等学校骨干教师资助计划(FUKT2000206)
